Overview

Solid Tumor 671 Gene Testing is a next-generation sequencing (NGS) service that profiles 671 cancer-related genes from a single tumor specimen. Instead of inspecting one biomarker at a time, the panel scans for point mutations, insertions and deletions, copy-number changes, and selected rearrangements across the genome. The output is a comprehensive molecular map that helps clinicians see which signaling pathways are actually driving a patient's disease. For oncology teams managing treatment-resistant or hard-to-classify solid tumors, this breadth converts a vague diagnosis into a concrete list of targetable findings. The service suits hospitals, pathology labs, and procurement teams that need reproducible genomic data without running their own sequencing facility.

How It Works

The workflow starts with nucleic-acid extraction from FFPE tissue, fresh tissue, or plasma ctDNA. Library preparation enriches the 671 target regions, and sequencing runs on a high-throughput platform with deep coverage to detect low-frequency variants. Bioinformatics pipelines then annotate each alteration, filter germline noise, and rank findings by clinical relevance. Turnaround usually spans two to three weeks from sample receipt. Because the panel interrogates both established drivers such as EGFR, BRAF, and KRAS and emerging targets, one report can surface several therapy routes at once. This breadth is why many programs adopt broad panels as a first-line profiling step before sequential single-gene assays.

Indications

The service supports adults with any solid tumor type where genomic guidance may inform care—non-small cell lung, colorectal, breast, gastric, biliary, and rare tumors alike. It is most valuable for patients whose standard pathology leaves no clear targeted option, those who have progressed on prior therapy, or individuals being considered for a biomarker-defined trial. Physicians also use the data to assess homologous-recombination deficiency and mismatch-repair status, which can widen eligibility for PARP and immunotherapy approaches. The test fits wherever a precise molecular picture would change treatment.

Dosage & Administration

This is a diagnostic service rather than a medication, so no dosing applies. A Pathology Request Form, signed consent, and one to three unstained FFPE slides (or a 10 mL cfDNA blood tube) are required per case. Reports are delivered electronically with variant tables, interpretive summaries, and references. Re-testing is recommended only on disease progression or when new tissue becomes available.

Storage & Sourcing

FFPE blocks should be stored at 2–8°C and shipped with cold packs; plasma samples require 2–8°C transport and prompt processing. The testing service is sourced through TreatmentsDrugs' verified manufacturer network, with documentation and QC certificates supplied per batch. Cross-border buyers receive export-compliant packaging and shipment tracking.

FAQ

Q: How is 671-gene testing different from a single-gene test? A: A single-gene test reports one marker; the 671-gene panel surveys hundreds of drivers simultaneously, often revealing several therapy routes within a single report.

Q: What sample types are accepted? A: FFPE tissue, fresh frozen tissue, and plasma ctDNA are all supported, giving flexibility when only limited material is available.

Q: How long until results return? A: Most cases report within two to three weeks of sample receipt, depending on specimen quality and the required depth of analysis.

Q: Can the report guide clinical-trial matching? A: Yes. The annotated variant list is commonly used to screen patients for biomarker-defined trials and expanded-access programs.